The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathogenetic studies have shown that Aβ peptide accumulation in the brain is an early and central event, 2”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [2]
In the citing paper
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.e., Aβ accumulation is necessary but insufficient to cause full-blown disease.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Karran et al., 2011
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [63]
In the citing paper
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [7]
In the citing paper
“a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Karran et al., 2011
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The discovery that AD could be inherited in an autosomal dominant fashio”
Background
Research works printed but not linked: 2
- Burns, A. & Ilife, S. Dementia. BMJ 338, 405–409 (2009).
- Alzheimer, A. About a peculiar disease of the cerebral cortex. [in German] Centralblatt für Nervenheilkunde Psychiatrie 30, 177–179 (1907).
Cited by
Items 701–800 of 1,007
Lazarev, V. F., Tsolaki, M., Mikhaylova, E. R., Benken, K. A., Shevtsov, M. A., Nikotina, A. D., Lechpammer, M., Mitkevich, V. A., Makarov, A. А., Moskalev, A., et al. (2021) · Aging and Disease · doi:10.14336/ad.2020.1230 · Cited by 41
“Accordingly, AD pathogenesis is triggered by the formation of soluble oligomers from physiologically monomeric Aβ molecules, followed by the generation of insoluble polymeric Aβ aggregates, eventually accumulating as amyloid plaques [4].”
BackgroundYi, S., Chen, S., Xiang, J., Tan, J., Huang, K., Zhang, H., Wang, Y., & Wu, H. (2021) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.a2021.0006 · Cited by 40
“Ab peptide fragments can induce neuronal cell death directly or indirectly [36], and oligomeric Ab peptides have been identified as a key factor in the multiple pathogenic changes in AD and, more generally, in dementia [37].”
BackgroundIs Cerebral Amyloid-β Deposition Related to Post-stroke Cognitive Impairment?
Ouyang, F., Jiang, Z., Chen, X., Chen, Y., Wei, J., Xing, S., Zhang, J., Fan, Y., & Zeng, J. (2021) · Translational Stroke Research · doi:10.1007/s12975-021-00921-5 · Cited by 43
Sun, Z., Tu, L., Zhuo, F.-J., & Liu, S.-X. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.001 · Cited by 42
Andrade-Talavera, Y., & Rodríguez-Moreno, A. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.696476 · Cited by 39
Dantrolene, A Treatment for Alzheimer Disease?
Li, L., & Wei, H. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000076 · Cited by 43
Lawrence, V. C., Pickett, J., Ballard, C. G., & Murray, J. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3958 · Cited by 43
“…and cost-effective symptomatic benefits (Ballard et al., 2011), but there no effective diseasemodifying treatments, and some of the most promising disease-modifying compounds have failed to show efficacy in phase III drug trials, despite promising pre-clinical data (Karran et al., 2011).”
BackgroundKiametis, A. S., Silva, M. A., Romeiro, L. A. S., Martins, J. B. L., & Gargano, R. (2017) · Journal of Molecular Modeling · doi:10.1007/s00894-017-3228-9 · Cited by 40
“Despite that the etiology of AD is not completely known, diverse factors including β-amyloid plaques [7, 8], τ -protein aggregation [9], oxidative stress [10, 11] and decreased levels of acetylcholine (ACh) [12] have been associated with the disease’s pathophysiology.”
BackgroundThe Effects of Soluble A.β Oligomers on Neurodegeneration in Alzheimer's Disease
Brouillette, J. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990498 · Cited by 41
“New therapeutic agents are currently being evaluated in clinical trials to prevent the formation and accumulation of toxic A oligomers in the brain [208].”
BackgroundAnti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects
Kozin, S. A., Barykin, E. P., Mitkevich, V. A., & Makarov, A. А. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918090079 · Cited by 40
The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration
Engstrom, A., Walker, A. C., Moudgal, R. A., Myrick, D. A., Kyle, S. M., Bai, Y., Rowley, M. J., & Katz, D. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013552117 · Cited by 40
“As dementia progresses, the spatial pattern of tau pathology highly 62 correlates with the level of cognitive impairment (10-13).”
BackgroundAluminum and Tau in Neurofibrillary Tangles in Familial Alzheimer’s Disease
Mold, M. J., O’Farrell, A., Morris, B., & Exley, C. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210011 · Cited by 49
Use of proteomic methods in the analysis of human body fluids in A lzheimer research
Zürbig, P., & Jahn, H. (2012) · Electrophoresis · doi:10.1002/elps.201200360 · Cited by 39
Increased Glutaminyl Cyclase Expression in Peripheral Blood of Alzheimer's Disease Patients
Valenti, M. T., Bolognin, S., Zanatta, C., Donatelli, L., Innamorati, G., Pampanin, M., Zanusso, G., Zatta, P. F., & Carbonare, L. D. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-120517 · Cited by 38
Good gene, bad gene: New APP variant may be both
Fede, G. D., Catania, M., Morbin, M., Giaccone, G., Moro, M. L., Ghidoni, R., Colombo, L., Messa, M., Cagnotto, A., Romeo, M., et al. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.004 · Cited by 45
Mazzitelli, S., Filipello, F., Rasile, M., Lauranzano, E., Cucuzza, C. S., Tamborini, M., Pozzi, D., Barajon, I., Giorgino, T., Natalello, A., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0381-9 · Cited by 39
“Although it is known that the number of amyloid plaques does not necessarily correlate with cognitive impairments ([60–62]; reviewed in [63]), the presence of amyloid deposits at the hippocampal level may explain the occurrence of the behavioral defects observed in injected in healthy mice.”
Li, Y., Li, Z.-X., Jin, T., Wang, Z.-Y., & Zhao, P. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-160804 · Cited by 38
“Keywords: Alzheimer’s disease, extracellular matrix, hyaluronan synthase, hyaluronic acid, tau pathology”
BackgroundGanglioside-Mediated Assembly of Amyloid β-Protein: Roles in Alzheimer's Disease
Matsuzaki, K., Kato, K., & Yanagisawa, K. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.10.005 · Cited by 39
Jiang, C., Ge, Y.-X., Cheng, Z., Song, J.-L., Wang, Y., Zhu, K., & Zhang, H. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00202-2 · Cited by 40
Predicting Amyloid-β Levels in Amnestic Mild Cognitive Impairment Using Machine Learning Techniques
Ezzati, A., Harvey, D. J., Habeck, C. G., Golzar, A., Qureshi, I., Zammit, A. R., Hyun, J., Truelove‐Hill, M., Hall, C. B., Davatzikos, C. A., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-191038 · Cited by 38
“…of participants, selection of an inappropriate biological target (i.e., merely reducing amyloid production or aggregation cannot modify disease progression) [5], enrollment of individuals based on unreliable criteria, and inclusion of individuals who did not have increased cerebral A…”
Liu, P., Zhao, B., Wei, M., Li, Y., Liu, J., Ma, L., Shang, S., Huo, K., Wang, J., Li, R., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191317 · Cited by 42
Jurcau, A., & Simion, A. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200303121016 · Cited by 38
de Montgolfier, O., Thorin‐Trescases, N., & Thorin, É. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa001 · Cited by 50
Pan, J., He, R., Huo, Q., Shi, Y., & Zhao, L. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03076-1 · Cited by 45
The role of microRNAs regulatory network in Alzheimer’s disease: a bioinformatics analysis
Sun, C., Qi, X., Liu, J., Duan, F., & Cong, L. (2021) · Archives of Medical Science · doi:10.5114/aoms/80619 · Cited by 64
Peptides for disrupting and degrading amyloids
Liang, C.-Q., & Li, Y. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.05.011 · Cited by 39
Wolframin is a novel regulator of tau pathology and neurodegeneration
Chen, S., Acosta, D. M., Li, L., Liang, J., Chang, Y., Wang, C., Fitzgerald, J., Morrison, C. T., Goulbourne, C. N., Nakano, Y., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02417-4 · Cited by 41
“Prevailing evidence suggests that Aβ acts primarily as a trigger of various downstream processes, in particular tau aggregation, which induces neurodegeneration [35, 49, 66].”
BackgroundInfluence of genetic and cardiometabolic risk factors in Alzheimer’s disease
Pasqualetti, G., Thayanandan, T., & Edison, P. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101723 · Cited by 41
“…to the formulation of the amyloid cascade hypothesis that poses the brain deposition of insoluble Aβ peptide as a primary event of the disease, which in turns leads to NFT and progressive neuronal damage (Glenner and Wong, 1984; Hardy and Selkoe, 2002; Karran et al. 2011; Scheltens et al., 2016).”
Role of PrPC Expression in Tau Protein Levels and Phosphorylation in Alzheimer’s Disease Evolution
Vergara, C., Ordóñez‐Gutiérrez, L., Wandosell, F. G., Ferrer, I., del Río, J. A., & Gavín, R. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8793-7 · Cited by 42
“The widely accepted amyloid cascade hypothesis posits that the deposition of Aβ in the brain parenchyma triggers a sequence of events leading to tau dysfunction [26, 27].”
BackgroundTailoring of Membrane Proteins by Alternative Splicing of Pre-mRNA
Mittendorf, K. F., Deatherage, C. L., Ohi, M. D., & Sanders, C. R. (2012) · Biochemistry · doi:10.1021/bi3007065 · Cited by 44
“While the etiology of the disease remains the subject of intense scrutiny, the amyloidogenic pathway appears to play a central role (100).”
Xue, D., Zhao, M., Wang, Y., Wang, L., Yang, Y., Wang, S., Zhang, R., Zhao, Y., & Liu, R. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.013 · Cited by 39
Guo, Q., Li, H., Cole, A. L., Hur, J.-Y., Li, Y., & Zheng, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080706 · Cited by 38
“According to the prevailing Aβ cascade hypothesis, excessive amount of Aβ peptides generated by mis-regulated APP metabolism is considered to be the initiating factor of AD pathogenesis, leading to Aβ plaque formation, tau hyperphosphorylation, and neurodegeneration [20].”
BackgroundC/EBPβ/AEP Signaling Drives Alzheimer’s Disease Pathogenesis
Xiong, J., Zhang, Z., & Ye, K. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01025-w · Cited by 37
β‐Amyloid pathogenesis: Chemical properties versus cellular levels
Tiwari, M. K., & Kepp, K. P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1895 · Cited by 37
“PSEN1 mutations almost exclusively increase the Ab42/ Ab40 ratio [11,12].”
BackgroundInfluentialCan insulin signaling pathways be targeted to transport Aβ out of the brain?
Vandal, M., Bourassa, P., & Calon, F. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00114 · Cited by 41
“However, individuals with very high levels of Aβ do not necessarily develop cognitive symptoms (Knopman et al., 2003; Price et al., 2009; Rentz et al., 2010; Karran et al., 2011; Chételat et al., 2013) because other protective mechanisms are in play, including the socalled cognitive reserve (Rentz et al.”
InfluentialTiepolt, S., Barthel, H., Butzke, D., Hesse, S., Patt, M., Gertz, H., Reininger, C. B., & Sabri, O. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2268-8 · Cited by 40
“accepted model explaining the development of AD [1].”
BackgroundKang, M. S., Baek, S., Chun, Y. S., Moore, A. Z., Landman, N., Berman, D. E., Yang, H. O., Morishima‐Kawashima, M., Osawa, S., Funamoto, S., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445734 · Cited by 40
“Thus, early intervention is becoming increasingly important, and there is a significant unmet need for effective and safe prophylactic as well as therapeutic approaches in AD (6, 7).”
BackgroundmNos2 Deletion and Human NOS2 Replacement in Alzheimer Disease Models
Colton, C. A., Wilson, J. G., Everhart, A., Wilcock, D. M., Puoliväli, J., Heikkinen, T., Oksman, J., Jääskeläinen, O., Lehtimäki, K., Laitinen, T., et al. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000094 · Cited by 37
Chauhan, K., Datta, A., Adhikari, A., Chuttani, K., Singh, A. K., & Mishra, A. K. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00941j · Cited by 37
Computational analysis of candidate prion-like proteins in bacteria and their role
Iglesias, V., de Groot, N. S., & Ventura, S. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01123 · Cited by 39
“Despite these polypeptides are diverse in function, sequence and origin, all share the propensity to form β -sheet aggregates (Karran et al., 2011).”
BackgroundNasaruddin, M. L., Hölscher, C., Kehoe, P. G., Graham, S. F., & Green, B. D. (2016) · Explore Bristol Research · Cited by 46
A β-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment
Montoliu-Gaya, L., & Villegas, S. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.11 · Cited by 37
“DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA Aducanumab (3-6, primary epitope) DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA Bapineuzumab (1-5) Solanezumab and crenezumab (16-26) N-t C-t CTF C99 CTF C83 C-t”
BackgroundCui, J., Wang, X., Li, X., Wang, X., Zhang, C., Li, W., Zhang, Y., Gu, H., Xie, X., Nan, F., et al. (2015) · Cell Discovery · doi:10.1038/celldisc.2015.21 · Cited by 37
Ansart, M., Epelbaum, S., Gagliardi, G., Colliot, O., Dormont, D., Dubois, B., Hampel, H., Durrleman, S., & study, F. T. A. D. N. I. A. T. I.-P. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280218823036 · Cited by 37
Li, X., Lu, J., Xu, Y., Wang, J., Qiu, X., Fan, L., Li, B., Liu, W., Mao, F., Zhu, J., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.07.006 · Cited by 40
“Morpholinyl containing derivative 12 was identified to display excellent p70S6K phosphorylation inhibitory activity (Table 1), so the 5-morpholinothiazole moiety (12) was retained in the following structural modification.”
BackgroundMethodKaur, G., & Prakash, A. K. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.108255 · Cited by 41
Lipid efflux mechanisms, relation to disease and potential therapeutic aspects
Castaño, D., Rattanasopa, C., Monteiro-Cardoso, V. F., Corlianò, M., Liu, Y., Zhong, A., Rusu, M., Liehn, E. A., & Singaraja, R. R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.013 · Cited by 38
Li, L., Miao, M., Chen, J., Liu, Z., Li, W., Qiu, Y., Xu, S., & Wang, Q. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15234 · Cited by 38
“…strategies have attempted to eliminate Aβ burden by preventing neuronal and synaptic loss, but the failure of these strategies suggests that amyloid pathology does not correlate well with memory and synaptic deficits in AD (Crimins et al., 2013; Karran et al., 2011; Kodamullil et al., 2017).”
BackgroundRoles of Long Non-coding RNAs in the Development of Aging-Related Neurodegenerative Diseases
Ni, Y., Xu, H., & Liu, Y. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.844193 · Cited by 42
Tau Positron Emission Tomography Imaging
Kolb, H. C., & Andrés, J. I. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a023721 · Cited by 37
“Ab peptide deposits are commonly found outside neurons in the brain, while tau protein tangles are formed inside neurons but eventually end up in the intercellular space after neuronal death (Karran et al. 2011).”
De Strooper, B., & Karran, E. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00057-w · Cited by 36
“The underlying conundrum is whether A β peptide and amyloid plaques are suf fi cient to trigger AD ( “ amyloid fi rst ” ) (Selkoe and Hardy, 2016; Karran et al, 2011), or whether PSEN dysfunction itself is the cause of neuronal dyshomeostasis and neurodegeneration ( “ presenilin fi rst ” ) (Shen and…”
BackgroundInfluentialSelf-citationJonson, M., Pokrzywa, M., Starkenberg, A., Hammarstrom, P., & Thor, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133272 · Cited by 36
“An overwhelming number of studies, using a multitude of approaches, has resulted in the general view that 1–40 is slowly aggregatory and has low toxicity in vivo, while 1–42 is very aggregation prone and highly toxic [5].”
BackgroundMarchesi, V. T. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.03.004 · Cited by 36
Jia, J., Cui, M., Dai, J., & Liu, B. (2015) · Dalton Transactions · doi:10.1039/c5dt00023h · Cited by 37
Svedružić, Ž. M., Popović, K., & Jengić, V. Š. (2013) · PLoS ONE · doi:10.1371/journal.pone.0050759 · Cited by 42
“The presented quantitative analysis of changes in the catalytic capacity of c-secretase, can be used for evaluation of the pathogenic potential of different cellular processes that affect Ab metabolism [10,58,71].”
BackgroundLu, Y.-S., Riddell, D., Hajós-Korcsok, É., Bales, K., Wood, K. M., Nolan, C. E., Robshaw, A. E., Zhang, L.-M., Leung, L. Y., Becker, S. L., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192625 · Cited by 37
“The amyloid cascade hypothesis postulates that Alzheimer’s disease (AD) is caused by abnormal accumulation and deposition of amyloid- (A ) in the brain (Hardy and Higgins, 1992; Karran et al., 2011).”
BackgroundUsing bacterial inclusion bodies to screen for amyloid aggregation inhibitors
Villar‐Piqué, A., Espargaró, A., Sabaté, R., de Groot, N. S., & Ventura, S. (2012) · Microbial Cell Factories · doi:10.1186/1475-2859-11-55 · Cited by 41
“The pathological hallmark of AD is brain deposition of amyloid plaques composed predominantly by the Aβ42 peptide isoform [8–10].”
Fernández, S. S. M., Ivanauskas, T. M., & Ribeiro, S. M. L. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.06.015 · Cited by 36
Chen, Y., Zhu, J., Mo, J., Yang, H., Jiang, X., Lin, H., Gu, K., Pei, Y., Wu, L., Tan, R. X., et al. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1412314 · Cited by 39
Nakahara, K., Fuchino, K., Komano, K., Asada, N., Tadano, G., Hasegawa, T., Yamamoto, T., Sako, Y., Ogawa, M., Unemura, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00011 · Cited by 40
Statins and Brain Health: Alzheimer’s Disease and Cerebrovascular Disease Biomarkers in Older Adults
Ramanan, V. K., Przybelski, S. A., Graff‐Radford, J., Castillo, A. M., Lowe, V. J., Mielke, M. M., Roberts, R. O., Reid, R. I., Knopman, D. S., Jack, C. R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180446 · Cited by 36
“This hypothesis draws on the importance of cholesterol and other lipids in amyloid pathways [1], population genetics findings including the strong association of the apolipoprotein E ( APOE ) (cid:2) 4 allele and other lipid-related genetic variants with AD [2–4], and animal and cellular experiments…”
Gerber, H., Mosser, S., Boury‐Jamot, B., Stumpe, M., Piersigilli, A., Goepfert, C., Dengjel, J., Albrecht, U., Magara, F., & Fraering, P. C. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0660-3 · Cited by 48
“and neuronal death, ultimately leading to dementia [2, 23, 24, 31, 51].”
BackgroundPrions and Neurodegenerative Diseases: A Focus on Alzheimer’s Disease
Crestini, A., Santilli, F., Martellucci, S., Carbone, E., Sorice, M., Piscopo, P., & Mattei, V. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215171 · Cited by 37
“The dynamics of these species and the poorly defined mechanisms of toxicity make this topic particularly controversial in this field [90].”
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 40
“In AD patients, the soluble neurotoxic oligomers’ formation generated by monomeric Aβmolecules is followed by insoluble polymeric Aβ aggregates’ formation, which tends to accumulate in amyloid plaques [62].”
BackgroundA Cell Model for the Initial Phase of Sporadic Alzheimer's Disease
Stockburger, C., Gold, V. A. M., Pallas, T., Kolesova, N., Miano, D., Leuner, K., & Müller, W. E. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140381 · Cited by 41
“Some groups have reported that an increased A 1-42/A 1-40 ratio could be more significant than the absolute A levels in promoting the onset of AD [40].”
Coskuner‐Weber, O., & Uversky, V. N. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.05.007 · Cited by 36
Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA
Sin, M., ZAMRINI, E. Y., Ahmed, A., Nho, K. T., & Hajjar, I. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216792 · Cited by 44
“Accumulation of amyloid β in the brain plays a key role in the pathogenesis of AD, synaptic dysfunction, neurodegeneration, and finally clinical symptoms [4–6].”
BackgroundLee, J., Lee, H., Lee, H. G., Shin, M., Shin, M.-G., Seo, J., Lee, E. J., Park, S. A., & Park, S. (2023) · Nature Communications · doi:10.1038/s41467-023-44319-3 · Cited by 42
“Production of amyloid beta (A β ) peptides in neurons and their senile amyloid beta plaque formation is a prominent hallmark of Alzheimer ’ s disease (AD) 1 , and it is known that inef fi cient clearance of toxic A β peptides from the brain contributes to initiation and progression of AD 2,3 .”
InfluentialGene networks and systems biology in Alzheimer's disease: Insights from multi‐omics approaches
Rahimzadeh, N., Srinivasan, S. S., Zhang, J., & Swarup, V. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13790 · Cited by 44
“6 The precise mechanisms underlying neuronal loss in AD remain incompletely understood, despite a host of mechanisms having been introduced.”
BackgroundTorres, M., Matamala, J. M., Duran-Aniotz, C. A., Cornejo, V. H., Foley, A., & Hetz, C. A. (2014) · Virus Research · doi:10.1016/j.virusres.2014.12.018 · Cited by 43
“…synapses and alter their function; they also can impair calcium homeostasis, and trigger detrimental processes, such as excitotoxicity, oxidative stress, ER stress and local inflammation (Cornejo and Hetz, 2013; Halliday and Mallucci, 2014; Hetz and Soto, 2006; Karran et al., 2011; Selkoe, 2001).”
BackgroundX-ray Crystallographic Structures of Oligomers of Peptides Derived from β2-Microglobulin
Spencer, R. K., Kreutzer, A. G., Salveson, P. J., Li, H., & Nowick, J. S. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b01673 · Cited by 34
Targeted Magnetic Nanoparticles for Remote Magnetothermal Disruption of Amyloid‐β Aggregates
Loynachan, C. N., Romero, G., Christiansen, M. G., Chen, R., Ellison, R., O’Malley, T. T., Froriep, U. P., Walsh, D. M., & Anikeeva, P. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500487 · Cited by 38
Lipids under stress – a lipidomic approach for the study of mood disorders
Miranda, A. M., & Oliveira, T. G. (2015) · BioEssays · doi:10.1002/bies.201500070 · Cited by 39
“Moreover, some cognitive disorders, such as AD, still rely on post-mortem evaluation for its diagnosis [111].”
BackgroundAberrant proteolytic processing and therapeutic strategies in Alzheimer disease
Tomita, T. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.01.001 · Cited by 37
Grasso, G. I., Bellia, F., Arena, G., Satriano, C., Vecchio, G., & Rizzarelli, E. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.060 · Cited by 36
Fuchino, K., Mitsuoka, Y., Masui, M., Kurose, N., Yoshida, S., Komano, K., Yamamoto, T., Ogawa, M., Unemura, C., Hosono, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00002 · Cited by 38
Roe, S. M., Wahab, B., Török, Z., Horváth, I., Vígh, L., & Prodromou, C. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00051 · Cited by 36
“Currently, it is thought that Aβ plaques, formed due to the aggregation of Aβ-precursor protein, trigger the hyperphosphorylation of Tau resulting in neurofibrillary tangle formation and neurotoxicity (Hardy and Selkoe, 2002; Selkoe, 2002; Oddo et al., 2003; Tanzi and Bertram, 2005; Annaert andDe Strooper, 2010; Jinwa…”
BackgroundMelatonin attenuates streptozotocin-induced Alzheimer-like features in hyperglycemic rats
Kamsrijai, U., Wongchitrat, P., Nopparat, C., Satayavivad, J., & Govitrapong, P. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104601 · Cited by 38
The Ambiguous Role of Microglia in Aβ Toxicity: Chances for Therapeutic Intervention
Merlo, S., Spampinato, S. F., Caruso, G. I., & Sortino, M. A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200131105418 · Cited by 37
Krishna, K. V., Saha, R. N., & Dubey, S. K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00430 · Cited by 36
Biflavonoid-Induced Disruption of Hydrogen Bonds Leads to Amyloid-β Disaggregation
Windsor, P. K., Plassmeyer, S. P., Mattock, D. S., Bradfield, J. C., Choi, E. Y., Miller, B. R., & Han, B. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062888 · Cited by 37
“Towards defining a fundamental molecular etiology of AD as a target for drug development, the amyloid cascade hypothesis has been a leading model for linking the deposition of amyloid β (Aβ) peptide with the onset of neurodegeneration and cognitive decline [3].”
BackgroundStructure and Function of Alzheimer’s Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review
Agrawal, N., & Skelton, A. A. (2019) · The Protein Journal · doi:10.1007/s10930-019-09854-3 · Cited by 24
Luteinizing hormone as a key player in the cognitive decline of Alzheimer's disease
Burnham, V. L., & Thornton, J. E. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.05.010 · Cited by 38
“Contents lists available at ScienceDirect Hormones and Behavior j ourna l homepage: www.e lsev ie r .com/ locate /yhbeh eventually leads to the development of Alzheimer's disease (Hardy and Selkoe, 2002; Hardy, 2009; Karran et al., 2011).”
MethodA golden age of muscarinic acetylcholine receptor modulation in neurological diseases
Tobin, A. B. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01007-1 · Cited by 47
“…abundant neuropathological and genetic evidence for the involvement of Aβ deposits in late-onset sporadic AD, supporting what is known as the amyloid cascade hypothesis 151,152 Therefore, the prospect that M 1 -receptor agonism might have an impact on amyloid pathology in AD is extremely exciting.”
Pettersson, M., Johnson, D. S., Humphrey, J. M., Butler, T. W., Ende, C. W. A., Fish, B. A., Green, M., Kauffman, G. W., Mullins, P. B., O’Donnell, C. J., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00070 · Cited by 36
Andreasen, N., Simeoni, M., Ostlund, H., Lisjo, P. I., Fladby, T., Loercher, A. E., Byrne, G. J., Murray, F., Scott-Stevens, P. T., Wallin, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0098153 · Cited by 34
“Several investigational treatments target Aβ [1].”
Liu, H., Chu, W., Gong, L., Gao, X., & Wang, W. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4860 · Cited by 39
“The predominant theory for the molecular mechanism underlying AD is the amyloid cascade hypothesis (5).”
Melanopsin retinal ganglion cell loss and circadian dysfunction in Alzheimer's disease (Review)
FENG, R., Li, L., Yu, H., Liu, M., & Zhao, W. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4966 · Cited by 36
“Other factors that may lead to Alzheimer's disease pathology are diabetes, hypertension, obesity, smoking and the presence of Alzheimer's disease in first‐degree relatives (15).”
BackgroundDual/Multitargeted Xanthone Derivatives for Alzheimer'S Disease: Where Do We Stand?
Cruz, M. I., Cidade, H. M., & Pinto, M. M. M. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0086 · Cited by 37
Royal jelly peptides: potential inhibitors of β-secretase in N2a/APP695swe cells
Zhang, X., Yu, Y., Sun, P., Fan, Z., Zhang, W., & Feng, C. (2019) · Scientific Reports · doi:10.1038/s41598-018-35801-w · Cited by 41
Krance, S. H., Cogo‐Moreira, H., Rabin, J. S., Black, S. E., & Swardfager, W. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.1056-19.2019 · Cited by 36
“, 1998), but not AD, implicating tau as a downstream effect of A , common across several dementia syndromes (Karran et al., 2011).”
BackgroundInfluentialKaur, A., Shuaib, S., Goyal, D., & Goyal, B. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp04775a · Cited by 35
Schwartz, M., Ramos, J. M. P., & Ben-Yehuda, H. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900844 · Cited by 34
Extracellular Vesicles as a Neprilysin Delivery System Memory Improvement in Alzheimer's Disease.
Izadpanah, M., Dargahi, L., Ai, J., Taei, A. A., Barough, S. E., Mowla, S. J., Tavoosidana, G., & Farahmandfar, M. (2020) · PubMed Central · doi:10.22037/ijpr.2020.112062.13508 · Cited by 40
Liang, P.-Z., Li, L., Zhang, Y., Shen, Y. H., Zhang, L., Zhou, J., Wang, Z.-J., Wang, S., & Yang, S. (2021) · Neural Plasticity · doi:10.1155/2021/9960304 · Cited by 39
Dong, Q., Li, Z., Zhang, Q., Hu, Y., Liang, H., & Xiong, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.924429 · Cited by 36
“It is well known that amyloid proteins are produced from the amyloid precursor (APP), a key biomolecule, through cleavage by βsecretase (β-APP- cleaving enzyme-1 (BACE1) at the ectodomain and γ-secretase at intra-membranous sites (Karran et al., 2011; Scheltens et al., 2016; Knopman et al., 2021; Leng and Edison, 2021…”
BackgroundThe Imbalance of Vascular Molecules in Alzheimer's Disease
Bell, R. D. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121060 · Cited by 34
“A longstanding principal hypothesis in AD research is the “Amyloid Hypothesis”, which basically states that the accumulation of cytotoxic A species in the brain is a central pathological event in AD [39–41].”
Beta-Amyloid Monomer and Insulin/IGF-1 Signaling in Alzheimer's Disease
Giuffrida, M. L., Tomasello, M. F., Caraci, F., Chiechio, S., Nicoletti, F., & Copani, A. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8313-6 · Cited by 35
“The majority of AD cases have a late onset and are sporadic [3], likely resulting from complex interactions of disease determinants with agerelated risk factors (e.”
BackgroundSaidi, L.-J., Polydoro, M., Kay, K. R., Sanchez, L., Mandelkow, E., Hyman, B. T., & Spires‐Jones, T. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142094 · Cited by 39
“Recent failures in amyloid directed therapeutics have rejuvenated the field of therapies aimed at reducing the pathological changes in tau [20].”
BackgroundPhotodynamic micelles for amyloid β degradation and aggregation inhibition
Zhang, J., Liu, J., Zhu, Y., Xu, Z., Xu, J., Wang, T., Yu, H., & Zhang, W. (2016) · Chemical Communications · doi:10.1039/c6cc06175c · Cited by 35
Metadata
- Authors
- Karran, E., Mercken, M., & Strooper, B. D.
- Affiliations
- Janssen (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Karran, Eric
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-19
- Volume
- 10
- Issue
- 9
- Pages
- 698-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2079749054
- Cited by
- 2,188
- References
- 157
- Citations by year
- 2026: 74 · 2025: 115 · 2024: 130 · 2023: 139 · 2022: 141 · 2021: 158 · 2020: 174 · 2019: 191 · 2018: 174 · 2017: 163 · 2016: 171 · 2015: 160 · 2014: 151 · 2013: 130 · 2012: 107
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, amyloid-beta aggregation, amyloid-beta production, clinical trial design, phase III trial failure, drug development
- MeSH terms
- Alzheimer Disease, Animals, Brain Chemistry, Humans, Research Design, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Age of Onset, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.